Party Drug Ketamine (Special K) Likely To Become Anti-Depression Medicine
The drug Ketamine, known in the party scene as "Special K," could have a future in depression treatment. Pharmaceutical companies are racing to create a patentable version of the drug and researchers are trying to learn more about the effects it has on the brain. Ketamine works by blocking the signalling molecule NMDA, which is a component of the glutamate pathway. This pathway is involved with memory and cognition, psychiatrist James Murrough at the Mount Sinai Hospital in New York City, explained to Nature magazine.
- Dr. James Murrough, Assistant Professor, Psychiatry, Neuroscience, Icahn School of Medicine at Mount Sinai
New Research Sheds Light on Why Eczema So Often Begins in Childhood
Feb 25, 2026 View All Press Releases
Research Identifies Blind Spots in AI Medical Triage
Feb 24, 2026 View All Press Releases
Mount Sinai Study May Help Cancer Patients Keep Their Bladder
Feb 19, 2026 View All Press Releases
Can Medical AI Lie? Large Study Maps How LLMs Handle Health Misinformation
Feb 09, 2026 View All Press Releases
Mount Sinai Scientists Uncover Link Between Influenza and Heart Disease
Feb 09, 2026 View All Press Releases